Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2005
10/20/2005CA2561203A1 New process for the preparation of diazine derivatives
10/20/2005CA2561164A1 Steroid sparing agents and their use
10/20/2005CA2561162A1 Method of treating schizophrenia and/or glucoregulatory abnormalities
10/20/2005CA2561159A1 Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases
10/20/2005CA2560995A1 Controlled release dosage for gaba receptor agonist
10/20/2005CA2560967A1 1-(1h-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1-phenyl propan-2-ol derivatives and related compounds as modulators of the norepinephrine (ne) and the serotonine (5-ht) activity andthe monoamine reuptake for the treatment of vasomotor symptoms (vms)
10/20/2005CA2560966A1 Heterocyclic phenylaminopropanol derivatives as modulators of the monoamine reuptake for the treatment of vasomotor symptoms (vms)
10/20/2005CA2560954A1 Certain triazole-based compounds, compositions, and uses thereof
10/20/2005CA2560941A1 Compositions as adjuvants to improve immune responses to vaccines and methods of use
10/20/2005CA2560796A1 Biaryl substituted pyrazinones as sodium channel blockers
10/20/2005CA2560727A1 Sequential sprm/progestin treatment
10/20/2005CA2560683A1 Novel benzothiazoles and the use thereof as medicaments
10/20/2005CA2560649A1 [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase
10/20/2005CA2560648A1 1,1'-(1,2-ethynediyl)bis-benzene derivatives as ptp 1-b inhibitors
10/20/2005CA2560416A1 Angiogenesis-affecting compounds and methods of use thereof
10/20/2005CA2560315A1 Combination therapies with epothilones and carboplatin
10/20/2005CA2560311A1 Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejection
10/20/2005CA2560162A1 Inhibitors of iap
10/20/2005CA2560131A1 Compounds for treating proliferative processes
10/20/2005CA2559741A1 A medical article having a bioactive agent-releasing component with photoreactive groups
10/20/2005CA2559740A1 Thiadiazolidinones as gsk-3 inhibitors
10/20/2005CA2559739A1 Deferasirox dispersible tablets
10/20/2005CA2559014A1 Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives
10/20/2005CA2558817A1 Crystalline forms of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
10/20/2005CA2558349A1 Pharmaceutical preparation containing drospirenone for application to the skin
10/20/2005CA2558244A1 Antiinflammatory lactones
10/20/2005CA2557850A1 Methods of treatment using eszopiclone
10/20/2005CA2557848A1 Ion binding compositions
10/20/2005CA2557845A1 Process for preparing, and composition and pharmaceutical dosage forms containing, an oxycodone salt having less than 25 ppm 14-hydroxycodeinone
10/20/2005CA2557721A1 Ion channel modulators
10/20/2005CA2557010A1 Compounds and methods for treating dyslipidemia
10/20/2005CA2556461A1 Spray dried pharmaceutical compositions
10/20/2005CA2555859A1 Compounds with atypical antipsychotic activity
10/20/2005CA2555390A1 Immunostimulatory viral rna oligonucleotides
10/20/2005CA2546150A1 Estrogen receptor modulators
10/19/2005EP1586644A2 Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour development and for wound healing
10/19/2005EP1586642A2 Tumor supressor genes, proteins encoded thereby and use of said genes and proteins
10/19/2005EP1586575A2 Salt of a sulfonic acid containing clopidogrel and use thereof for the preparation of pharmaceutical compositions
10/19/2005EP1586574A1 Medicaments containing betamimetic drugs and a novel anticholinesterase drug
10/19/2005EP1586573A1 Oxadiazolones, processes for their preparation and their use as pharmaceuticals
10/19/2005EP1586572A1 Fused pyrazolyls as anti-cancer drugs
10/19/2005EP1586571A1 Dipeptidyl peptidase inhibitors
10/19/2005EP1586567A1 Compounds useful in the treatment of inflammatory diseases
10/19/2005EP1586565A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
10/19/2005EP1586564A1 8-azaprostaglandin derivatives and medicinal uses thereof
10/19/2005EP1586561A1 Bicyclic aromatic sulfinyl derivatives
10/19/2005EP1586560A1 Thio-substituted arylmethanesulfinyl derivatives
10/19/2005EP1586559A1 Biaryl-methanethio-, -sulphinyl- and sulphonyl derivatives
10/19/2005EP1586558A2 Bis-sulfonamide hydroxyethylamino retroviral protease inhinitors
10/19/2005EP1586557A1 4-nitro-2- (4 -methoxy)-phenoxy -methanesulfonanilide derivates and their pharmaceutical use
10/19/2005EP1586556A2 Compounds to treat Alzheimer's disease
10/19/2005EP1586550A1 Lipoxin compounds and their use
10/19/2005EP1586349A1 Controlled release of anti-arrhythmic agents
10/19/2005EP1586347A1 Electrically assisted lidocaine and epinephrine delivery device having extended shelf-stability
10/19/2005EP1586337A2 The local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque
10/19/2005EP1586332A1 Combined use of carnosinase inhibitor with l-carnosines and composition
10/19/2005EP1586323A1 Use of fulvestrant in the treatment of resistant breast cancer
10/19/2005EP1586322A2 Compositions for inhibition of anglogenesis
10/19/2005EP1586321A1 New use of glutamate antagonists for the treatment of cancer
10/19/2005EP1586320A1 Cytisine containing solid dosage form
10/19/2005EP1586319A1 Thiadiazolidinones as GSK-3 inhibitors
10/19/2005EP1586318A1 Thiadiazolidinones as GSK-3 inhibitors
10/19/2005EP1586317A1 Oral compositions comrising L-carnitine and a xanthine
10/19/2005EP1586316A1 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
10/19/2005EP1586315A1 Skin lightening composition
10/19/2005EP1586314A1 Nateglinide tablet composition
10/19/2005EP1586313A1 Pharmaceutical composition with metoclopramide and process for its preparation
10/19/2005EP1586312A1 Agent for dissolving dental calculi and dental caries
10/19/2005EP1586310A1 Method to manufacture valsartan adsorbates in the form of a free-flowing powder
10/19/2005EP1586307A2 Cosmetic or pharmaceutical compositions containing preserved taurine
10/19/2005EP1585955A2 Use of isogenic human cancer cells for high-throughput screening and drug discovery
10/19/2005EP1585827A2 Modulation of protein functionalities
10/19/2005EP1585817A2 Conjugates comprising a biodegradable polymer and uses therefor
10/19/2005EP1585814A1 Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals
10/19/2005EP1585757A2 Peptide deformylase inhibitors
10/19/2005EP1585753A2 Novel semisynthetic macrolide antibiotics of the azalide series
10/19/2005EP1585752A1 Polyene polyketides, processes for their production and their use as a pharmaceutical
10/19/2005EP1585750A2 Narcistatin prodrugs
10/19/2005EP1585749A1 Diazepinoindole derivatives as kinase inhibitors
10/19/2005EP1585745A1 Fc receptor modulating compounds and compositions
10/19/2005EP1585743A1 2-(1h-indazol-6-ylamino)- benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
10/19/2005EP1585740A2 Process to prepare psorospermin
10/19/2005EP1585734A2 Anti-inflammatory medicaments
10/19/2005EP1585732A2 Spermicidal and/or antifungal composition and methods of using the same
10/19/2005EP1585728A1 Imino acid derivatives for use as inhibitors of matrix metalloproteinases
10/19/2005EP1585727A1 Indoles useful in the treatment of androgen-receptor related diseases
10/19/2005EP1585724A2 Method of reducing toxicity of retinoids
10/19/2005EP1585723A2 Modified retinoid compounds and their uses
10/19/2005EP1585713A1 New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists
10/19/2005EP1585560A2 Delivery of molecules and complexes to mammalian cells in vivo
10/19/2005EP1585548A2 Compositions and methods of delivery of pharmacological agents
10/19/2005EP1585545A2 Methods of inducing and maintaining immune tolerance
10/19/2005EP1585541A2 Pharmaceutical compositions comprising insulin and legends of insulin hexamer
10/19/2005EP1585532A2 Topical anti-infective formulations
10/19/2005EP1585531A1 Biocompatible dialysis fluids containing icodextrins
10/19/2005EP1585530A2 Bioadhesive pharmaceutical compositions
10/19/2005EP1585529A2 Process for the production of 2'-branched nucleosides
10/19/2005EP1585528A1 Use of sphingomyelin and lyso-sphingomyelin as absorption enhancers
10/19/2005EP1585527A1 Compositions and methods for combination antiviral therapy
10/19/2005EP1585526A2 Novel use of mifepristone and derivatives thereof as hedgehog protein signalling pathway modulators and applications of same
1 ... 4499 4500 4501 4502 4503 4504 4505 4506 4507 4508 4509 4510 4511 4512 4513 4514 4515 4516 4517 4518 4519 ... 7860